Psilocybin

DB11664InvestigationalSmall molecule

Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Chemical structure of Psilocybin
Mechanism
Curator reviewed
Formula / weight
C12H17N2O4P · 284.2481 g/mol (avg)
Also known as
Indocybin · Psilocybine
Code names
CY-39 · DEA No. 7437 · PEX010 · TRP-8802 · TRYP-0082

Resolves to

Compound
UNII2RV7212BP0CAS520-52-5ChEMBLCHEMBL194378ChEBI8614PubChem10624KEGGC07576
Structure
InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-NSMILESCN(C)CCC1=CNC2=C1C(OP(O)(O)=O)=CC=C2
Targets
P28223HTR2A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
666Drug interactionsStructured to mechanism, not free text
Sign in
248Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Psilocybin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In